Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2000

View Archived Issues

Coulter's CPI-0004Na prodrug shows promising preclinical profile

Collgard updates development status of halofuginone

Periodontix tests sustained silver delivery for periodontitis

Cambridge Discovery Chemistry moves forward in deal with AstraZeneca

Butyrylcholinesterase inhibition heralded as potential new treatment strategy for AD

Interferon alfa-2b offers protection from eye involvement in Behcet's disease

Phase III results in for pleconaril: ViroPharma reaffirms commitment to novel antiviral drug

BioTransplant initiates phase I/II trial of AlloMune

Approval of Gliadel Wafer in Spain triggers milestone payment to Guilford

U.S. researchers design PDGF-binding antitumor and antiangiogenic compound

Celsion completes expanded phase I trial for BPH therapy

TLC-144, a new ceramide derivative, induces apoptosis in tumor cells by activating specific caspase

NIDA recommends Nabi-NicVAX funding for treatment and prevention of nicotine dependence

Plant extract in active development at Ozelle for cancer profiled at AACR meeting

Tamiflu launched in Latin America

Iron chelator undergoing evaluation as antitumor agent by U.S. researchers

Novel angiogenesis inhibitor discussed by Eisai at recent cancer meeting

Loss of hepatitis B antigen increases with increasing duration of lamivudine therapy

New sulfonylureidopyrazoles for endothelin-related disorders

Potent antitumor agents produced by microorganism discovered by Snow Brand

Organoselenium compounds as antioxidants, cytoprotective agents presented by Oxis

BE-70016: new antitumor compound produced by strain of Actinoplanes

Chimeric GRF analogues with enhanced potency designed by Theratechnologies

Nippon Soda discloses newest agents for lipid disorders

Antiasthmatics in early development at Tanabe Seiyaku

WHI study continues despite early increase in cardiac events with HRT

FDA approves Visudyne therapy for treatment of AMD